NONPARAMETRIC TESTING FOR MULTIPLE SURVIVAL FUNCTIONS WITH NON-INFERIORITY MARGINS.
Ontology highlight
ABSTRACT:
SUBMITTER: Chang HW
PROVIDER: S-EPMC6580843 | biostudies-literature | 2019 Feb
REPOSITORIES: biostudies-literature
Publications
NONPARAMETRIC TESTING FOR MULTIPLE SURVIVAL FUNCTIONS WITH NON-INFERIORITY MARGINS.
Chang Hsin-Wen HW McKeague Ian W IW
Annals of statistics 20181130 1
New nonparametric tests for the ordering of multiple survival functions are developed with the possibility of right censorship taken into account. The motivation comes from non-inferiority trials with multiple treatments. The proposed tests are based on nonparametric likelihood ratio statistics, which are known to provide more powerful tests than Wald-type procedures, but in this setting have only been studied for pairs of survival functions or in the absence of censoring. We introduce a novel t ...[more]
Similar Datasets
Project description:BackgroundThe reporting of randomised controlled non-inferiority (NI) drug trials is poor with less than 50% of published trials reporting a justification of the NI margin. This is despite the introduction of the Consolidated Standards of Reporting Trials (CONSORT) extension on reporting of NI and equivalence in randomised trials. It is critical to set the appropriate NI margin as this choice dictates the conclusions of the trial. Methods to estimate the margin are heterogeneous but generally based on clinical judgement and statistical reasoning, and hence tailored to each clinical situation. Yet an appraisal of NI in clinical trials has not been undertaken. Therefore the aim of this systematic review is to assess the reporting and methodological quality of defining the NI margin. Surgical NI trials have been chosen as our prototype to assess this.MethodsWe will conduct a systematic review of published randomised controlled trials in abdominal surgery that use an NI design. Key eligibility criteria will be: surgical intervention in at least one trial arm; adult patients and a sample size of 100 or more. Ovid MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials will be searched from inception until the date of the search. Identified studies will be assessed for reporting according to the CONSORT recommendations. The outcomes are the description of the methods for defining the NI margin, and the robustness of the NI margin estimation. The latter will be based on simulations using alternative assumptions for model parameters. The results of the simulation will be compared with the trial authors' conclusions.Anticipated resultsThe review will describe and appraise the design and reporting of surgical NI trials including shortcomings thereof and allow a comparison with pharmaceutical trials. These findings will inform researchers on the appropriate design and pitfalls when conducting surgical randomised controlled trials with an NI design and promote thorough and standardised reporting of study findings.Ethics and disseminationEthical approval is not required and any changes to the protocol will be communicated via the registration platform. The final manuscript will be submitted to a journal for publication and the findings will be disseminated through conference presentations to inform researchers and the public.
| S-EPMC11344494 | biostudies-literature
Project description:The need for analysis of multiple responses arises from many applications. In behavioral science, for example, comorbidity is a common phenomenon where multiple disorders occur in the same person. The advantage of jointly analyzing multiple correlated responses has been examined and documented. Due to the difficulties of modeling multiple responses, nonparametric tests such as generalized Kendall's Tau have been developed to assess the association between multiple responses and risk factors. These procedures have been applied to genomewide association studies of multiple complex traits. Unfortunately, those nonparametric tests only provide the significance of the association but not the magnitude. We propose a Gaussian copula model with discrete margins for modeling multivariate binary responses. This model separates marginal effects from between-trait correlations. We use a bootstrapping margins approach to constructing Wald's statistic for the association test. Although our derivation is based on the fully parametric Gaussian copula framework for simplicity, the underlying assumptions to apply our method can be weakened. The bootstrapping margins approach only requires the correct specification of the model margins. Our simulation and real data analysis demonstrate that our proposed method not only increases power over some existing association tests, but also provides further insight into genetic association studies of multivariate traits.
| S-EPMC4629876 | biostudies-literature
Project description:ObjectiveTo describe the size and variability of non-inferiority margins used in non-inferiority trials of medications with primary outcomes involving mortality, and to examine the association between trial characteristics and non-inferiority margin size.DesignSystematic review.Data sourcesMedline, Medline In Process, Medline Epub Ahead of Print and Embase Classic+Embase databases from January 1989 to December 2019.Eligibility criteriaProspective non-inferiority randomised controlled trials comparing pharmacological therapies, with primary analyses for non-inferiority and primary outcomes involving mortality alone or as part of a composite outcome. Trials had to prespecify non-inferiority margins as absolute risk differences or relative to risks of outcome and provide a baseline risk of primary outcome in the control intervention.Results3992 records were screened, 195 articles were selected for full text review and 111 articles were included for analyses. 82% of trials were conducted in thrombosis, infectious diseases or oncology. Mortality was the sole primary outcome in 23 (21%) trials, and part of a composite primary outcome in 88 (79%) trials. The overall median non-inferiority margin was an absolute risk difference of 9% (IQR 4.2%-10%). When non-inferiority margins were expressed relative to the baseline risk of primary outcome in control groups, the median relative non-inferiority margin was 1.5 (IQR 1.3-1.7). In multivariable regression analyses examining the association between trial characteristics (medical specialty, inclusion of paediatric patients, mortality as a sole or part of a composite primary outcome, presence of industry funding) and non-inferiority margin size, only medical specialty was significantly associated with non-inferiority margin size.ConclusionAbsolute and relative non-inferiority margins used in published trials comparing medications are large, allowing conclusions of non-inferiority in the context of large differences in mortality. Accepting the potential for large increases in outcomes involving mortality while declaring non-inferiority is a challenging methodological issue in the conduct of non-inferiority trials.
| S-EPMC8061825 | biostudies-literature
Project description:The use of non-motorized vehicles in urban city has improved the convenience of short-distance travel and reduced traffic pollution. However, the overtaking behaviour of non-motorized vehicles impacts traffic safety and efficiency significantly. The objective of this study is to model the durations of overtaking behaviour in the non-motorized vehicle exclusive lane. A total of 3010 overtaking events of non-motorized vehicles were extracted from two locations in Chengdu, China. The nonparametric survival analysis was conducted to model the overtaking duration of non-motorized vehicles. The categorical variables that significantly influence the overtaking duration were examined by the Log-rank test. The results show that the overtaking durations of female riders is longer than that of male riders. It takes longer for electrical bikes to complete overtaking than conventional bikes. When the non-motorized vehicle is under the load state (i.e. passengers or goods on the non-motorized vehicle), the overtaking behaviour takes more time than the un-load state. Moreover, it takes less time to overtake the non-motorized vehicle with load than to overtake the one without load. When there is a wrong-way driving phenomenon or under higher traffic volume, the duration is longer compared to the normal traffic and lower traffic volume conditions. The findings of this study attempt to provide a more profound understanding of non-motorized vehicles overtaking behaviour under different traffic conditions and give insights to the safety research of non-motorized vehicles.
| S-EPMC7845977 | biostudies-literature
Project description:With the availability of limited resources, innovation for improved statistical method for the design and analysis of randomized controlled trials (RCTs) is of paramount importance for newer and better treatment discovery for any therapeutic area. Although clinical efficacy is almost always the primary evaluating criteria to measure any beneficial effect of a treatment, there are several important other factors (e.g., side effects, cost burden, less debilitating, less intensive, etc.), which can permit some less efficacious treatment options favorable to a subgroup of patients. This leads to non-inferiority (NI) testing. The objective of NI trial is to show that an experimental treatment is not worse than an active reference treatment by more than a pre-specified margin. Traditional NI trials do not include a placebo arm for ethical reason; however, this necessitates stringent and often unverifiable assumptions. On the other hand, three-arm NI trials consisting of placebo, reference, and experimental treatment, can simultaneously test the superiority of the reference over placebo and NI of experimental treatment over the reference. In this article, we proposed both novel Frequentist and Bayesian procedures for testing NI in the three-arm trial with Poisson distributed count outcome. RCTs with count data as the primary outcome are quite common in various disease areas such as lesion count in cancer trials, relapses in multiple sclerosis, dermatology, neurology, cardiovascular research, adverse event count, etc. We first propose an improved Frequentist approach, which is then followed by it's Bayesian version. Bayesian methods have natural advantage in any active-control trials, including NI trial when substantial historical information is available for placebo and established reference treatment. In addition, we discuss sample size calculation and draw an interesting connection between the two paradigms.
| S-EPMC8759450 | biostudies-literature
Project description:The problem of nonparametric inference on a monotone function has been extensively studied in many particular cases. Estimators considered have often been of so-called Grenander type, being representable as the left derivative of the greatest convex minorant or least concave majorant of an estimator of a primitive function. In this paper, we provide general conditions for consistency and pointwise convergence in distribution of a class of generalized Grenander-type estimators of a monotone function. This broad class allows the minorization or majoratization operation to be performed on a data-dependent transformation of the domain, possibly yielding benefits in practice. Additionally, we provide simpler conditions and more concrete distributional theory in the important case that the primitive estimator and data-dependent transformation function are asymptotically linear. We use our general results in the context of various well-studied problems, and show that we readily recover classical results established separately in each case. More importantly, we show that our results allow us to tackle more challenging problems involving parameters for which the use of flexible learning strategies appears necessary. In particular, we study inference on monotone density and hazard functions using informatively right-censored data, extending the classical work on independent censoring, and on a covariate-marginalized conditional mean function, extending the classical work on monotone regression functions.
| S-EPMC7377427 | biostudies-literature
Project description:Background/aims Non-inferiority trials with time-to-event outcomes are becoming increasingly common. Designing non-inferiority trials is challenging, in particular, they require very large sample sizes. We hypothesized that the difference in restricted mean survival time, an alternative to the hazard ratio, could lead to smaller required sample sizes. Methods We show how to convert a margin for the hazard ratio into a margin for the difference in restricted mean survival time and how to calculate the required sample size under a Weibull survival distribution. We systematically selected non-inferiority trials published between 2013 and 2016 in seven major journals. Based on the protocol and article of each trial, we determined the clinically relevant time horizon of interest. We reconstructed individual patient data for the primary outcome and fit a Weibull distribution to the comparator arm. We converted the margin for the hazard ratio into the margin for the difference in restricted mean survival time. We tested for non-inferiority using the difference in restricted mean survival time and hazard ratio. We determined the required sample size based on both measures, using the type I error risk and power from the original trial design. Results We included 35 trials. We found evidence of non-proportional hazards in five (14%) trials. The hazard ratio and the difference in restricted mean survival time were consistent regarding non-inferiority testing, except in one trial where the difference in restricted mean survival time led to evidence of non-inferiority while the hazard ratio did not. The median hazard ratio margin was 1.43 (Q1-Q3, 1.29-1.75). The median of the corresponding margins for the difference in restricted mean survival time was -21?days (Q1-Q3, -36 to -8) for a median time horizon of 2.0?years (Q1-Q3, 1-3?years). The required sample size according to the difference in restricted mean survival time was smaller in 71% of trials, with a median relative decrease of 8.5% (Q1-Q3, 0.4%-38.0%). Across all 35 trials, about 25,000 participants would have been spared from enrollment using the difference in restricted mean survival time compared to hazard ratio for trial design. Conclusion The margins for the hazard ratio may seem large but translate to relatively small differences in restricted mean survival time. The difference in restricted mean survival time offers meaningful interpretation and can result in considerable reductions in sample size. Restricted mean survival time-based measures should be considered more widely in the design and analysis of non-inferiority trials with time-to-event outcomes.
| S-EPMC6133762 | biostudies-literature
Project description:An important inferential task in functional linear models is to test the dependence between the response and the functional predictor. The traditional testing theory was constructed based on the functional principle component analysis which requires estimating the covariance operator of the functional predictor. Due to the intrinsic high-dimensionality of functional data, the sample is often not large enough to allow accurate estimation of the covariance operator and hence causes the follow-up test underpowered. To avoid the expensive estimation of the covariance operator, we propose a nonparametric method called Functional Linear models with U-statistics TEsting (FLUTE) to test the dependence assumption. We show that the FLUTE test is more powerful than the current benchmark method (Kokoszka P,2008; Patilea V,2016) in the small or moderate sample case. We further prove the asymptotic normality of our test statistic under both the null hypothesis and a local alternative hypothesis. The merit of our method is demonstrated by both simulation studies and real examples.
| S-EPMC7319281 | biostudies-literature
Project description:Three-arm non-inferiority (NI) trial including the experimental treatment, an active reference treatment, and a placebo where the outcome of interest is binary are considered. While the risk difference (RD) is the most common and well explored functional form for testing efficacy (or effectiveness), however, recent FDA guideline suggested measures such as relative risk (RR), odds ratio (OR), number needed to treat (NNT) among others, on the basis of which NI can be claimed for binary outcome. Albeit, developing test based on these different functions of binary outcome are challenging. This is because the construction and interpretation of NI margin for such functions are non-trivial extensions of RD based approach. A Frequentist test based on traditional fraction margin approach for RR, OR and NNT are proposed first. Furthermore a conditional testing approach is developed by incorporating assay sensitivity (AS) condition directly into NI testing. A detailed discussion of sample size/power calculation are also put forward which could be readily used while designing such trials in practice. A clinical trial data is reanalyzed to demonstrate the presented approach.
| S-EPMC6867690 | biostudies-literature
Project description:For censored survival outcomes, it can be of great interest to evaluate the predictive power of individual markers or their functions. Compared with alternative evaluation approaches, approaches based on the time-dependent receiver operating characteristics (ROC) rely on much weaker assumptions, can be more robust, and hence are preferred. In this article, we examine evaluation of markers' predictive power using the time-dependent ROC curve and a concordance measure that can be viewed as a weighted area under the time-dependent area under the ROC curve profile. This study significantly advances from existing time-dependent ROC studies by developing nonparametric estimators of the summary indexes and, more importantly, rigorously establishing their asymptotic properties. It reinforces the statistical foundation of the time-dependent ROC-based evaluation approaches for censored survival outcomes. Numerical studies, including simulations and application to an HIV clinical trial, demonstrate the satisfactory finite-sample performance of the proposed approaches.
| S-EPMC3743052 | biostudies-literature